Management of Elevated Testosterone Levels

Rationale for Therapy Pause

The American College of Clinical Oncology recommends that patients should not receive therapies that modulate testosterone levels for a minimum of 1 year before considering resumption of treatment, to allow for normalization of testosterone levels and minimize potential health risks 1, 2, 4
Recovery of normal testosterone levels after cessation of therapy is highly variable between individuals, with older age and prolonged androgen deprivation associated with longer recovery times, according to the Journal of Clinical Oncology 3, 5
A testosterone level of 2500 ng/dL is significantly above both the normal physiologic range and the minimum threshold recommended for clinical trial eligibility, as stated by the Journal of Urology 3, 6

Serial testosterone measurements should be obtained to monitor the decline in testosterone levels, with the goal of reaching a plateau or returning to the pretreatment baseline, as recommended by the Journal of Clinical Oncology 3, 4, 5, 7
Some clinicians define stabilization as when two consecutive testosterone measurements are within 10% of each other, according to the Journal of Clinical Oncology 3, 4

Therapy should only be resumed once testosterone levels have normalized to the middle tertile of the normal reference range, as recommended by the Journal of Urology 6
If fertility is a concern, exogenous testosterone therapy should be avoided as it suppresses spermatogenesis, according to the Journal of Urology 8, 9
Recovery of spermatogenesis after testosterone therapy cessation can take months or rarely years, as stated by the Journal of Urology 9

For patients requiring continued treatment for testosterone deficiency while maintaining fertility potential, consider human chorionic gonadotropin (hCG) injections, selective estrogen receptor modulators (SERMs), or aromatase inhibitors, as recommended by the Journal of Urology 6, 9

Exogenous testosterone at high levels may be associated with potential cardiovascular concerns requiring a 3-6 month waiting period after cardiac events, as stated by the Journal of Urology 6